UNSPSC 51342801: Aranotin

This classification denotes an antiviral agent with the molecular formula C20H18N2O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H56CKB2FFV, chemically known as 5,5a,13,13a-tetrahydro-5,13-dihydroxy-8h,16h-7a,15a-epidithio-7h,15h-bisoxepino(3,4:4,5)pyrrolo(1,2-a:1,2-d)pyrazine-7,15-dione 5-acetate but generally known as aranotin, which bears US NIH Compound Identifier 29844. European Medicines Agency schedules Aranotin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05551MIG.

UNSPSC 51342801 Aranotin, a Commodity code, does not align with state and local procurement activity in the source material. The recent opportunities tagged under this code involve naloxone and drug deactivation systems, pharmacy benefit program administration, medical and first aid supplies for emergency response, and generic pharmaceutical distribution — none of which constitute aranotin procurement. The code shows little relevant recent activity; the mismatch between the nominal commodity and the actual solicitations suggests either a data-entry error in the state and local procurement system or that the code is not being used as intended for genuine aranotin buys.

State and local issuing bodies posting opportunities under this code include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), a city fire rescue division (City of Tampa), and a multistate cooperative purchasing alliance (Minnesota MMCAP). The geographic spread spans Florida, Texas, and Minnesota, with Oregon participating through the MMCAP cooperative vehicle. Recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems with a response date of July 26, 2023; the City of Tampa's ITB for medical and first aid supplies (estimated $700,000, response date March 13, 2026); the Texas HHS Commission's RFI on direct-to-manufacturer pharmacy prescriptions (response date April 3, 2026); and the Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (response date March 26, 2026). Given the absence of aranotin-specific solicitation language across all opportunities, firms should verify code assignment with prospective customers before pursuing opportunities under this code.